Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial
Open Access
- 18 July 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 36 (36), 2463-2469
- https://doi.org/10.1093/eurheartj/ehv295
Abstract
AimsPatients with type 2 diabetes mellitus (T2DM) are at high risk of developing cardiovascular (CV) and renal disease. We examined the burden of, and risk of death following, CV and renal events in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE), a randomized trial of alikiren vs. placebo.Methods and resultsWe followed 8561 patients with T2DM and evidence of chronic kidney disease, CV disease, or both in ALTITUDE until the first non-fatal CV or renal event of myocardial infarction (MI), stroke, heart failure (HF), and end-stage renal disease (ESRD; initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL) and then to death or censoring. Time-updated multivariable Cox models were used to estimate the relative risk of death following each event. In total 1008 patients (12%) experienced at least one first non-fatal CV or renal event (4.1% HF, 2.8% MI, 2.8% stroke, and 2.2% ESRD). Death occurred subsequently in 26.4% of those experiencing a first HF event, 29.7% of those experiencing an MI event, 23.7% of those experiencing a stroke, and 14.7% of those experiencing ESRD, and in 6.5% (488) of the 7553 patients (88%) who did not experience a non-fatal CV or renal event. Compared with patients who did not experience a non-fatal event, the adjusted hazard ratio for death was 5.9 (95% confidence interval 4.6–7.6) after HF, 9.7 (7.5–12.6) after MI, 7.1 (5.3–9.5) after stroke, and 5.8 (3.7–9.0) after ESRD.ConclusionThe majority of deaths occurred in patients who did not experience a non-fatal CV or renal event, although the risk of death was higher following an event. Our findings illustrate continuing opportunities to reduce morbidity and mortality in patients with type 2 diabetes.Keywords
This publication has 37 references indexed in Scilit:
- Improved Survival and Renal Prognosis of Patients With Type 2 Diabetes and Nephropathy With Improved Control of Risk FactorsDiabetes Care, 2014
- Changes in Diabetes-Related Complications in the United States, 1990–2010New England Journal of Medicine, 2014
- Heart failure: a cardiovascular outcome in diabetes that can no longer be ignoredThe Lancet Diabetes & Endocrinology, 2014
- Time-Dependent Impact of Diabetes on Mortality in Patients With StrokeDiabetes Care, 2012
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesThe Lancet, 2010
- Development of Congestive Heart Failure in Type 2 Diabetic Patients With Microalbuminuria or ProteinuriaDiabetes Care, 2003
- Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)Kidney International, 2003
- Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial InfarctionCirculation, 2000
- Risk of End-stage Renal Disease in Diabetes MellitusJAMA, 1997
- Trends in Prevalence of Diabetes Mellitus in Patients with Myocardial Infarction and Effect of Diabetes on Survival: The Minnesota Heart SurveyDiabetes Care, 1991